CTXR

+ Watchlist + Portfolio

Citius Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.64
52-Week Range: $0.47 – $2.19
Market Cap: $16.47M
P/E (TTM): —
EPS (TTM): -1.64
Dividend Yield: —

Advanced Metrics

Price/Book: 0.16
PEG Ratio: —
Return on Equity: -83.60%
Return on Assets: -27.63%
Gross Margin: 80.07%
Operating Margin: -1827.78%
Profit Margin: 0.00%
Current Ratio: 0.58
Debt/Equity: 0.01
Total Debt: $808.16K
Free Cash Flow: $-33.46M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $24.50M

CTXR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.66M	$14.82M	$11.91M	$9.16M
Selling, General & Admin	$15.66M	$21.91M	$30.09M	$29.37M
Operating Expenses	$33.32M	$36.73M	$42.00M	$38.53M
Operating Income	-$33.32M	-$36.73M	-$42.00M	-$38.53M
EBITDA	-$33.14M	-$36.54M	-$41.79M	-$38.20M
Pretax Income	-$33.06M	-$31.97M	-$38.85M	-$38.68M
Income Tax	$576.00K	$576.00K	$576.00K	$1.06M
Net Income	-$33.64M	-$32.54M	-$39.14M	-$37.43M
Diluted EPS	-5.75	-5.57	-5.97	-3.38
Diluted Shares	5.84M	6.05M	6.73M	11.07M

CTXR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$41.71M	$26.48M	$3.25M	$4.25M
Inventory	—	$0.00	$8.27M	$22.29M
Current Assets	$44.56M	$34.37M	$14.22M	$27.93M
Total Assets	$114.00M	$103.61M	$116.65M	$130.94M
Current Liabilities	$4.53M	$5.78M	$35.81M	$44.91M
Total Debt	$678.23K	$481.25K	$262.87K	$1.81M
Total Liabilities	$10.57M	$12.18M	$42.55M	$53.41M
Retained Earnings	-$129.69M	-$162.23M	-$201.37M	-$238.80M
Shareholders' Equity	$102.83M	$90.83M	$70.08M	$67.55M
Working Capital	$40.03M	$28.59M	-$21.59M	-$16.98M

CTXR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.36M	-$29.06M	-$28.20M	-$26.55M
Free Cash Flow	-$28.36M	-$29.06M	-$28.20M	-$26.55M
Depreciation & Amortisation	$179.68K	$194.32K	$209.61K	$214.25K
Stock-Based Compensation	$3.91M	$6.62M	$11.84M	$10.84M
Investing Cash Flow	$0.00	$0.00	-$5.00M	-$5.75M
Financing Cash Flow	$0.00	$13.83M	$9.97M	$33.30M
Net Change in Cash	-$28.36M	-$15.23M	-$23.23M	$1.00M

CTXR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$3.94M	$1.67M
Cost of Revenue	$0.00	—	—	$789.21K	$328.88K
Gross Profit	$0.00	—	—	$3.15M	$1.34M
Research & Development	$3.77M	$1.62M	$1.64M	$1.60M	$1.63M
Selling, General & Admin	$7.49M	$7.17M	$6.80M	$10.00M	$30.18M
Operating Expenses	$11.26M	$8.79M	$8.44M	$12.17M	$33.53M
Operating Income	-$11.26M	-$8.79M	-$8.44M	-$9.02M	-$32.19M
EBITDA	-$11.19M	-$8.73M	-$8.32M	-$8.40M	-$26.59M
Pretax Income	-$11.25M	-$8.94M	-$8.48M	-$9.13M	-$28.34M
Income Tax	$264.24K	$264.24K	$264.24K	$264.24K	-$231.21K
Net Income	-$10.92M	-$8.79M	-$7.96M	-$8.22M	-$21.23M
Diluted EPS	-1.27	-0.80	—	-0.38	-0.95
Diluted Shares	8.58M	11.01M	—	21.50M	22.38M

CTXR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$26.41K	$6.09M	$4.25M	$7.72M	$4.59M
Receivables	—	—	—	$4.05M	$1.08M
Inventory	$15.34M	$17.21M	$22.29M	$22.64M	$22.66M
Current Assets	$18.37M	$24.61M	$27.93M	$37.95M	$31.69M
Total Assets	$121.48M	$127.68M	$130.94M	$140.39M	$132.54M
Current Liabilities	$49.88M	$51.84M	$44.91M	$38.21M	$55.02M
Total Debt	$931.79K	$1.88M	$1.81M	$1.83M	$808.16K
Total Liabilities	$57.91M	$60.12M	$53.41M	$46.92M	$63.46M
Retained Earnings	-$222.05M	-$230.84M	-$238.80M	-$247.02M	-$268.26M
Shareholders' Equity	$60.66M	$65.06M	$67.55M	$79.96M	$61.54M
Working Capital	-$31.50M	-$27.23M	-$16.98M	-$261.99K	-$23.33M

CTXR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.54M	-$5.41M	-$11.88M	-$13.01M	-$1.30M
Free Cash Flow	-$4.54M	-$5.41M	-$11.88M	-$13.01M	-$1.30M
Depreciation & Amortisation	$56.01K	$41.37K	$62.04K	-$16.48K	$40.66K
Stock-Based Compensation	$2.70M	$2.72M	$2.89M	$4.28M	$3.79M
Investing Cash Flow	$0.00	—	—	-$4.40M	-$600.00K
Financing Cash Flow	$3.47M	$11.47M	$15.79M	$20.88M	-$1.23M
Net Change in Cash	-$1.07M	$6.06M	-$1.84M	$3.47M	-$3.13M

Market Snapshot

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing critical care products. Based in Cranford, New Jersey, the company focuses on anti-infectives, cancer care, and prescription products. Citius Pharmaceuticals' pipeline includes treatments for acute bacterial skin infections, hemorrhagic cystitis, and other conditions requiring urgent medical intervention. The company pursues both novel formulations and improved delivery mechanisms for existing therapeutic compounds.